Table 3 |
|||
|
Patient's characteristics of matched HIV-seropositive patients and HIV-seronegative patients matched for TNM-stage and age (n = 10 vs. 10). |
|||
| Variable |
Study group |
Fisher's exact test |
|
|
|
|||
| HAART-HIV + |
HIV - |
||
|
|
|||
| gender |
m:f = 9:1 (90%) |
m:f = 1:9 (10%) |
0.001 |
| age (mean) |
44.5 +/- 10 y |
45.2 +/- 7 y |
NS |
| WHO-perform. Status I° |
2 (20 %) |
0 |
NS |
| T1 |
2 |
2 |
NS |
| T2 |
6 |
6 |
NS |
| T3 |
2 |
2 |
NS |
| N0 |
9 |
9 |
NS |
| N2 |
1 |
1 |
NS |
| G1 |
2 |
NS |
|
| G2 |
6 |
8 |
NS |
| G3 |
2 |
NS |
|
| Sphincter invasion |
2 (22 %) |
3 (30 %) |
NS |
| Histology (basaloid) |
2 (20 %) |
4 (40 %) |
NS |
| Mitomycin C |
6 (60 %) |
8 (80 %) |
NS |
| Brachytherapy |
0 (0 %) |
6 (60 %) |
0.005 |
| RT-dose (mean) |
57.7 +/- 2.4 Gy |
58.5 +/- 3 Gy |
NS |
Oehler-Jänne et al. Radiation Oncology 2006 1:29 doi:10.1186/1748-717X-1-29 |
|||
